| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 4th January 2021 | Jeffrey Alan Wolf | 288,100 | Grant/award etc. | $0.00 | |
| 4th January 2021 | John K A Prendergast | 138,272 | Grant/award etc. | $0.00 | |
| 12th November 2020 | Edward B Iii Smith | 103,304 | Open or private sale | $1.03 | $106,403.12 |
| 13th August 2020 | William L. Ostrander | 4,440 | Payment by withholding | $1.83 | $8,125.20 |
| 13th August 2020 | William L. Ostrander | 15,625 | Exercise of derivative | $0.52 | $8,125.00 |
| 16th June 2020 | John K A Prendergast | 99,000 | Grant/award etc. | $0.00 | |
| 2nd January 2020 | Jeffrey Alan Wolf | 1,980,000 | Grant/award etc. | $0.00 | |
| 2nd January 2020 | John K A Prendergast | 400,000 | Grant/award etc. | $0.00 | |
| 31st December 2019 | Jeffrey Alan Wolf | 900,000 | Grant/award etc. | $0.00 | |
| 24th June 2019 | John K A Prendergast | 84,000 | Grant/award etc. | $0.00 |
Heat Biologics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Heat Biologics, Inc. is a clinical stage company. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot. Its product candidates are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.
Ticker: HTBX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1476963
Employees: 36
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
